eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2010
vol. 14
 
Share:
Share:
abstract:
Review paper

Pharmacogenetics in breast cancer hormone therapy

Anna Supernat
,
Marzena Wełnicka-Jaśkiewicz
,
Anna Żaczek

Współczesna Onkologia (2010) vol. 14;4 (242-247)
Online publish date: 2010/09/09
View full text Get citation
 
PlumX metrics:
Malignant neoplasms are the second leading cause of death in Poland. Breast cancer constitutes 21.5% of all cancer incidence and 13.1% of mortality, which makes it the most common tumour among women. Although new methods of diagnostics and treatment extend the recurrence-free survival and survival rate, it still occurs that a prescribed drug fails to bring satisfactory effects. Pharmacogenetics, the study of genetic variation that gives rise to differing responses to treatment, can help decrease the number of patients who will not benefit from costly therapy due to their genetic predispositions. In the case of hormone therapy administered to breast cancer patients, the most intensively studied genes are: CYP2D6, CYP3A4, CYP3A5, SULT1A1, UGT1A4, UGT2B15 and CYP19. Thus far, a correlation between a particular allele and drug response has been proven only for genes CYP2D6 and CYP19.
keywords:

breast cancer, hormone therapy, pharmacogenetics, polymorphism

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.